Close Menu

NEW YORK (GenomeWeb) – Autoimmune rheumatic disease diagnostics firm Exagen Diagnostics filed a preliminary prospectus on Friday for an initial public offering of up to $69 million.

The company has not yet priced its shares or said how many shares it plans to offer. It said that it anticipates its stock to trade on the Nasdaq Global Market under ticker symbol "EXDX."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.